Sat Kartar Shopping Ltd
Incorporated in June 2012, Sat Kartar Shopping Limited is an Ayurveda healthcare company that delivers natural wellness solutions for therapeutic and lifestyle products.[1]
- Market Cap ₹ 307 Cr.
- Current Price ₹ 195
- High / Low ₹ 242 / 130
- Stock P/E 31.2
- Book Value ₹ 32.7
- Dividend Yield 0.00 %
- ROCE 39.9 %
- ROE 32.2 %
- Face Value ₹ 10.0
Pros
- Company has a good return on equity (ROE) track record: 3 Years ROE 47.8%
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Half Yearly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| 52 | 83 | 128 | 163 | |
| 49 | 78 | 118 | 149 | |
| Operating Profit | 3 | 5 | 10 | 14 |
| OPM % | 5% | 6% | 8% | 9% |
| 0 | 0 | 0 | 1 | |
| Interest | 0 | 0 | 1 | 1 |
| Depreciation | 1 | 1 | 1 | 1 |
| Profit before tax | 2 | 3 | 9 | 13 |
| Tax % | 7% | 27% | 27% | 25% |
| 1 | 3 | 6 | 10 | |
| EPS in Rs | 1.99 | 3.59 | 22.54 | 6.24 |
| Dividend Payout % | 0% | 0% | 3% | 11% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 46% |
| TTM: | 27% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 90% |
| TTM: | 58% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 48% |
| Last Year: | 32% |
Balance Sheet
Figures in Rs. Crores
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| Equity Capital | 0.70 | 0.70 | 3 | 16 |
| Reserves | 0 | 3 | 7 | 36 |
| 8 | 4 | 2 | 6 | |
| 3 | 8 | 11 | 6 | |
| Total Liabilities | 12 | 15 | 22 | 64 |
| 5 | 4 | 4 | 6 | |
| CWIP | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 1 |
| 8 | 11 | 18 | 57 | |
| Total Assets | 12 | 15 | 22 | 64 |
Cash Flows
Figures in Rs. Crores
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| 7 | -5 | |||
| -3 | -0 | |||
| -3 | 34 | |||
| Net Cash Flow | 2 | 28 |
Ratios
Figures in Rs. Crores
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| Debtor Days | 1 | 0 | 7 | 13 |
| Inventory Days | 31 | 25 | 23 | 185 |
| Days Payable | 165 | 226 | 237 | 170 |
| Cash Conversion Cycle | -134 | -200 | -208 | 29 |
| Working Capital Days | 14 | -8 | -3 | 40 |
| ROCE % | 50% | 98% | 40% |
Documents
Announcements
-
Clarification - Financial Results
23 June 2025 - Exchange has sought clarification from Sat Kartar Shopping Limited for the quarter ended 31-Mar-2025 with respect to Regulation 33 of the SEBI (LODR) Regulations, 2015. …
-
Press Release
20 June 2025 - ₹1 Cr capex for Ayurvedic capsule facility, 50% in-house production, plans for nutraceuticals expansion.
-
Press Release
11 June 2025 - Sat Kartar acquires Ajooni Life Sciences (₹5L) and increases Plantomed stake to 76% (₹90L) in June 2025.
-
Acquisition-XBRL
29 May 2025 - SAT KARTAR SHOPPING LIMITED has informed regarding Acquisition
-
Updates
29 May 2025 - Sat Kartar acquires 100% of Ajooni Life Sciences for Rs. 5 lakhs, making it a wholly-owned subsidiary.
Annual reports
No data available.
Concalls
-
May 2025Transcript PPT REC
Business Model[1]
The company operates in the Ayurveda healthcare sector using a Direct-to-Consumer (D2C) model, combining Ayurvedic principles with modern research. It focuses on product innovation, branding, and marketing while outsourcing manufacturing to trusted partners, adopting an asset-light strategy.